Trivedi and colleagues [26] replaced FBS with 20% human albumin during the ASC expansion for clinical use to treat diabetes, whereas Tzouvelekis and colleagues [27] used autologous platelet-rich plasma for the cell expansion to treat patients with pulmonary fibrosis. This evidence concerns the gene ALB and diabetes mellitus.